Results 61 to 70 of about 23,927 (264)

Emerging treatments for essential thrombocythemia

Journal of Blood Medicine, 2011
Steven Okoli, Claire HarrisonDepartment of Haematology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UKAbstract: In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe a disorder ...
Okoli S, Harrison C
doaj  

Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia

Hematology Reports, 2022
Essential thrombocythemia, as defined by the WHO in 2016, is a Philadelphia-negative chronic myeloproliferative neoplasm showing a better prognosis than polycythemia vera and myelofibrosis.
Marco Santoro, Vincenzo Accurso, Salvatrice Mancuso, Mariasanta Napolitano, Marta Mattana, Giorgia Vajana, Federica Russello, Sergio Siragusa   +7 more
doaj   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Budd-Chiari Syndrome in the Cirrhosis Stage Revealing Essential Thrombocythemia [PDF]

, 2021
A Rkiouak, N Sahel, Kassimi I El, M Zaizae, Y. Sekkach   +4 more
openalex   +1 more source

Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40‐year‐old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long‐term safety for EF.
Maryam Sahebari, Motahhareh Karimoddini, Naser Tayyebi Meibodi, Sajad Ataei Azimi, Shadan Tafreshian   +4 more
wiley   +1 more source

Successful management of VTE with essential thrombocythemia and cavernous transformation of the portal vein in early pregnancy: a case report

BMC Women's Health
Due to the thrombohemorrhagic potential of essential thrombocythemia, pregnancy complicated by essential thrombocythemia should be recognized as a risk factor for obstetric complications.
Xin Kang, Shibin Hong, Chengxi Tan, Wen Di, Ning Zhang   +4 more
doaj   +1 more source

The role of oxidative stress in essential thrombocythemia [PDF]

Archives of the Balkan Medical Union, 2018
In patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia, current studies have demonstrated a JAK2V617F-dependent reactive oxygen species (ROS) elevation partially mediated by a decrease in catalase expression associated ...
Cornel Moisă, Mihnea-Alexandru Găman, Emilia Georgiana Pascu, Oana Cătălina Drăgușin, Alexandru Dan Assani, Mirela-Elena Epîngeac, Amelia-Maria Găman   +6 more
doaj  

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

Haematologica, 2017
The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life.
Holly L. Geyer, Heidi Kosiorek, Amylou C. Dueck, Robyn Scherber, Stefanie Slot, Sonja Zweegman, Peter AW te Boekhorst, Zhenya Senyak, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Döhner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo Muxi, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Chiara Paoli, Francesco Passamonti, Bjorn Andreasson, Maria L Ferrari, Alessandro Rambaldi, Jan Samuelsson, Keith Cannon, Gunnar Birgegard, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Jean-Jacques Kiladjian, Peihong Zhang, Robert Peter Gale, Ruben A. Mesa   +51 more
doaj   +1 more source

Improved Diagnosis of the Transition to JAK2V617F Homozygosity: The Key Feature for Predicting the Evolution of Myeloproliferative Neoplasms [PDF]

, 2013
Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera and primary myelofibrosis are associated with JAK2V617F mutations.
Bianchini, Michele, de Brasi, Carlos Daniel, Gargallo, Patricia Martha, Gonzalez, Mariana Selena, Larripa, Irene Beatriz, Stanganelli, Carmen Graciela, Zalcberg, Ilana   +6 more
core   +3 more sources

Diagnosis and Management of Essential Thrombocythemia: A Comprehensive Review [PDF]

Documenta Haematologica
Myeloproliferative neoplasms, including essential thrombocythemia, are characterized by clonal proliferations of hematopoietic stem cells, leading to an increase in mature myeloid lineage cells.
Sandra LAZAR, Despina Calamar POPOVICI, Oana SARAU, Hortensia IONITA, Claudiu Octavian IONITA, Dacian Nicolae OROS, Ioana IONITA   +6 more
doaj   +1 more source